Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognitionESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozymeThe x-ray structure of the adduct between NAMI-A and carbonic anhydrase provides insights into the reactivity of this metallodrug with proteinsDeterminants for Tight and Selective Binding of a Medicinal Dicarbene Gold(I) Complex to a Telomeric DNA G-Quadruplex: a Joint ESI MS and XRD InvestigationCarbonic anhydrase inhibitorsDNA as a possible target for antitumor ruthenium(III) complexesTargeting aquaporin function: potent inhibition of aquaglyceroporin-3 by a gold-based compoundCharacterization of CA XIII, a novel member of the carbonic anhydrase isozyme familyCyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents.Carbonic anhydrase inhibitors: the first on-resin screening of a 4-sulfamoylphenylthiourea library.Carbonic anhydrase inhibitors: aliphatic N-phosphorylated sulfamates--a novel zinc-anchoring group leading to nanomolar inhibitors.Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease.Solution behaviour and biomolecular interactions of two cytotoxic trans-platinum(II) complexes bearing aliphatic amine ligands.Designing of novel carbonic anhydrase inhibitors and activators.Reactivity of anticancer metallodrugs with serum proteins: new insights from size exclusion chromatography-ICP-MS and ESI-MSThe molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics.BODIPY-phosphane as a versatile tool for easy access to new metal-based theranostics.The formation of oxytocin dimers is suppressed by the zinc-aspartate-oxytocin complex.Sulfonamides and sulfonylated derivatives as anticancer agents.Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.Conjugation of organoruthenium(II) 3-(1H-benzimidazol-2-yl)pyrazolo[3,4-b]pyridines and indolo[3,2-d]benzazepines to recombinant human serum albumin: a strategy to enhance cytotoxicity in cancer cells.Biophysical characterisation of adducts formed between anticancer metallodrugs and selected proteins: new insights from X-ray diffraction and mass spectrometry studies.Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.Potential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies.Proteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.Molecular mechanisms and proposed targets for selected anticancer gold compounds.Next-generation anticancer metallodrugs.Exploring the mechanisms of metal-based pharmacological agents via an integrated approach.Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs.A golden future in medicinal inorganic chemistry: the promise of anticancer gold organometallic compounds.Cellular transport mechanisms of cytotoxic metallodrugs: an overview beyond cisplatin.Reactivity and biological properties of a series of cytotoxic PtI2(amine)2 complexes, either cis or trans configured.Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexesExploring the gating mechanisms of aquaporin-3: new clues for the design of inhibitors?New Luminescent Polynuclear Metal Complexes with Anticancer Properties: Toward Structure-Activity Relationships.Evaluation of New Palladium Cages as Potential Delivery Systems for the Anticancer Drug Cisplatin.Insights into the strong in-vitro anticancer effects for bis(triphenylphosphane)iminium compounds having perchlorate, tetrafluoridoborate and bis(chlorido)argentate anions.Gold(I) NHC-based homo- and heterobimetallic complexes: synthesis, characterization and evaluation as potential anticancer agents.Adjusting the DNA Interaction and Anticancer Activity of Pt(II) N-Heterocyclic Carbene Complexes by Steric Shielding of the Trans Leaving Group.
P50
Q27643006-8B20F3C8-88FD-4DBE-8DF7-9C182BA0C077Q27643373-AC283F36-5584-43A0-B792-D07D03D33361Q27664948-287FA598-C7DD-4BCF-BDE9-AFE100F7AB1EQ27704204-DAB8AC9A-919E-45C9-869C-B211B6E30A28Q28219057-9548B9C0-08B8-4608-BE25-28872F7B666BQ28373954-EDA366C3-AB07-4509-8A00-220305CCC4E8Q28483815-26DA20A8-778B-420D-AD8C-052C9079ADE2Q28513669-AA63F7C5-5823-4640-8A14-4C519A782644Q30722799-C04A34C5-283E-494A-A5B7-05D4C55356B6Q31117406-2523F4D0-73DB-44E4-BBBE-BB75B5ED9F7CQ33208132-414AD235-42F2-4748-98E9-9CA32A093D19Q33429534-C5B2BE71-96EE-461B-A990-0BC2F701AE11Q33490676-28F24215-CD21-42F4-B3E8-F71CA9141D4EQ34343296-7933A4C4-8F58-436F-A6D6-4D95FF4EE78DQ34394993-9D6D9F58-5619-488A-8C91-4CE2E2C8288AQ34473297-A222B5C4-A942-469D-8867-3974F60B8C0CQ34509157-9D5997E0-A493-4506-BEDC-98556E8C079FQ34669877-4B711F0E-BBAD-4D09-9B67-E116E4717431Q34790789-A5D1A724-8D9C-45DB-A625-E1B7CEF42268Q35146735-F2524DBE-2AFB-466A-8A04-AAB31B03251DQ35664830-D1E193DE-49BB-4723-9082-04716A2D9CB0Q37090711-102E3BF7-CB18-47D1-BE11-A93FCB1ECD93Q37269801-F2A4E942-F748-4806-B9B9-B808DC9A9EE0Q37432620-50791961-F72E-4F33-921C-D8CF8DF5CC0BQ37563171-5FC9E3D1-E99A-45D1-AEB1-90B6AE8CB07CQ37576021-FE65303C-B869-43DD-B0CF-AAAF0E1356A6Q37951055-417C802D-BE5A-43A6-A8D3-9A741C7AF14DQ37974966-A777F1D5-9642-48D6-BEE8-26A1518F3B8EQ37985154-963F9023-0D91-4CB2-8C63-7D41B06D6B19Q38105454-3419BC2D-1AC4-46A6-BD81-F075FA537732Q38162354-F741D19C-4646-4038-B8CD-BBD1CBA0A79AQ38255538-7540EA07-44FD-4395-9390-343414386426Q38328964-93235456-DF7E-4F4B-80B4-ACB9DFE4D662Q38693266-CB0FE5EF-8C5E-4535-9FE5-22D5E3AB7C3AQ38787550-4B0DE336-2E2F-4089-83F6-19023CF3BA8EQ38795037-48B3D15E-7CA6-4640-99E8-E175FE0F7F94Q38804479-0E67FD60-F19E-44AE-8EDE-653BA89BAB99Q38834370-7D87FC5D-CAD3-44D4-AFCA-DDA1F3F67255Q38850175-060514EC-6604-4B02-B717-876ECC9B2752Q38852237-E96B83D1-C4DA-49ED-BF7A-09331CB49268
P50
description
medicinal and inorganic chemist and researcher
@en
onderzoeker
@nl
հետազոտող
@hy
name
Angela Casini
@ast
Angela Casini
@en
Angela Casini
@es
Angela Casini
@nl
type
label
Angela Casini
@ast
Angela Casini
@en
Angela Casini
@es
Angela Casini
@nl
altLabel
A. Casini
@nl
prefLabel
Angela Casini
@ast
Angela Casini
@en
Angela Casini
@es
Angela Casini
@nl
P108
P214
P1053
E-6731-2014
P106
P1153
7103318807
P1280
P21
P214
P2381
P31
P3829
P496
0000-0003-1599-9542
P569
1973-01-01T00:00:00Z
P734
P735
P7449
PRS1332276
P7859
lccn-no2015097950